Sign up USA
Proactive Investors - Run By Investors For Investors

Soligenix shares skyrocket on RiVax development program news

Ricin is an extremely dangerous poison, which has been used as a weapon and by terrorists.
Soligenix shares skyrocket on RiVax development program news
Ricin has been used as a biological weapon

Soligenix Inc (NASDAQ:SNGX) shares surged over 52% in New York as it posted positive data on its ricin toxin vaccine called RiVax.

Ricin is an extremely dangerous poison, which has been used as a  weapon and by terrorists.

It  can be inhaled, injected, ingested, or absorbed through eyes or damaged skin.

A vaccine against it is hoped to deter its use as a biological weapon.

The firm has shown RiVax has enhanced thermostability and 100% protection in pre-clinical ricin aerosol challenge models and will be showcasing results from the candidate's development program at a conference in Bethesda, Maryland  from April 24  to 26.

It is hoped the findings will aid approval of RiVax by the US Food and Drug Administration (FDA).

Shares added 52.87% to $3.93.

View full SNGX profile View Profile

Soligenix Timeline

Related Articles

researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use